Kymera Therapeutics, Inc.
KYMR
Classificação em ações
#2166
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Preço da ação
$114.00
Valor de mercado
$9.38B
Variação (1 dia)
0.48%
Variação (1 ano)
95.47%
País
US
Negociar Kymera Therapeutics, Inc. (KYMR)
Categoria
Healthcare
Receita da Kymera Therapeutics, Inc. (KYMR)
Receita em Jun 2026 TTM: $104.99M
De acordo com os últimos relatórios financeiros da Kymera Therapeutics, Inc., a receita atual da empresa (TTM) é $104.99M. Em 2023, a empresa obteve uma receita de $78.59M um aumento em relação a a receita do ano 2022, que foi de $46.83M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Kymera Therapeutics, Inc. de 2018 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $104.99M | 123.04% |
| 2024 | $47.07M | -40.11% |
| 2023 | $78.59M | 67.84% |
| 2022 | $46.83M | -35.71% |
| 2021 | $72.83M | 114.00% |
| 2020 | $34.03M | 1,059.99% |
| 2019 | $2.93M | 0.00% |
| 2018 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 11,924.40% |
US
|
|
| $2.23B | 2,022.13% |
US
|
|
| $15.74B | 14,896.17% |
AU
|
|
| $6.02B | 5,635.16% |
NL
|
|
| - | - |
CH
|
